Genetic polymorphism of the inhibitory IgG Fc receptor FccRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 723-727

  Weng, Wen Kai ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody based immunotherapy; FcR; Follicular lymphoma; Immunotherapy; Lymphoma and Hodgkin disease; Polymorphism; Rituximab

Indexed keywords

FC RECEPTOR IIB; ISOLEUCINE; RITUXIMAB; THREONINE;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FOLLICULAR LYMPHOMA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, IGG; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68449103580     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902829441     Document Type: Article

References (26)

1. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-708.
2. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G-M, Bernasconi S, et al. Biological response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-3908.
3. Weng W-K, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non- Hodgkin lymphoma. Blood 2001;98:1352-1357.
4. Manches O, Lui G, Chaperot L, Gressin R, Molens J-P, Jacob M-C, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949-954.
5. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti- CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgR IIIa gene. Blood 2002;99:754-758.
6. Weng W-K, Levy R. Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.
7. Fanger MW, Shen L, Graziano RF, Guyre PM. Cytotoxicity mediated by human Fc receptors for IgG. Trend Immunol 1989;10:92-99.
8. Graziano RF, Ranger MW. FcgRI and FcgRII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. J Immunol 1987;139:3536-3541.
9. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne A, de Haas M. FcgRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell FcgRIIIa, independently of the FcgRIIIa-48 L/R/H phenotype. Blood 1997;90:1109-1114.
10. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. J Biol Chem 2001;276:6591-6604.
11. Vance BA, Huizinga TWJ, Wardwell K, Guyre PM. Binding of monomeric human IgG defines an expression polymorphism of FcgRIII on large granular lymphocyte/natural killer cells. J Immunol 1993;151:6429-6439.
12. Nimmerjahn F, Ravetch JV. Fcg receptors: Old friends and new family members. Immunity 2006;24:19-28.
13. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Yamaguchi A, Fukazawa T, et al. Fcg receptor gene polymorphism in Japanese patients with systemic lupus erythematosus: Contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002;46:1242-1254.
14. Li X, Wu J, Carter RH, Edberg JC, Su K, Cooper GS, et al. A novel polymorphism in the Fcg receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum 2003;48:3242-3252.
15. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:1244-1253.
16. Kopreski MS, Benko FA, Kwee C, Leitzel KE, Eskander E, Lipton A, et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 1997;76:1293-1299.
17. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptor modulate in vivo cytotoxicity against tumor targets. Nature Med 2000;6:443-446.
18. Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K, et al. FcgRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Human Mol Gene 2005;14:2881-2892.
19. Camilleri-Broet S, Mounier N, Delmer A, Briere J, Casasnovas O, Cassard L, et al. FcgRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP + rituximab (R-CHOP). Leukemia 2004;18:2038-2040.
20. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M. Evidence for linkage disequilibrium between FcgRIIIa-V158F and FcgRIIA-H131R polymorphisms in white patients, and for an FcgIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008;26: 5489-5491.
21. van der Pol WL, Jansen MD, Sluiter WJ, van de Sluis B, Leppers-van de Straat FGJ, Kobayashi T, et al. Evidence for non-random distribution of Fcg receptor genotype combinations. Immunogenetics 2003;55:240-246.
22. Miescher S, Spycher MO, Amstutz H, de Haas M, Kleijer M, Kalus UJ, et al. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphism in the FcgRIIA and FcgRIIIA genes. Blood 2004;103:4028-4035.
23. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragement C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-1796.
24. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expression metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-3718.
25. Weng W-K, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004;22:4717-4724.
26. Chu ZT, Tsuchiya N, Kyogoku C, Ohashi J, Wian YP, Xu SB, et al. Association of Fcg receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in Chinese: A common susceptibility gene in the Asian populations. Tissue Antigens 2004;63:21-27.